ロード中...
Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1)
[Image: see text] In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an unfulfilled necessity. Here, we present novel types of protein–drug conjugates (PDCs) that exhibit...
保存先:
| 出版年: | Mol Pharm |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Chemical
Society
2020
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7588128/ https://ncbi.nlm.nih.gov/pubmed/32501706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.0c00419 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|